ABSTRACT
Patients with left ventricular assist devices (LVADs) who require intermittent hemodialysis (iHD) are considered to have a poor prognosis despite a paucity of supportive evidence, mostly from small single-center cohorts and extrapolations from studies of patients who received continuous renal replacement therapy but no iHD. We conducted a systematic review and individual-participant-data meta-analysis of the literature including our single-center cohort to examine the outcomes of patients initiated on iHD following LVAD implantation. Sixty-four patients from 5 cohorts met selection criteria (age 57.5 [46-64.5] years, 87% HeartMate II, mostly bridge to transplantation). Follow-up after iHD initiation was 87.5 (38.5-269.5) days, although it was considerably longer in our center than in other cohorts (601.5 [93-1559] days vs 65 [26-180] days, Pâ¯=â¯0.0007). The estimated median survival was 308 (76-912.5) days and varied significantly among cohorts, ranging from 60 (57-65) to 838 (103-1872) days (Pâ¯=â¯0.0096). Twelve (18.8%) patients achieved either heart transplantation (HT) or remission during follow-up. Patients who received HT had an 8-fold longer estimated median survival (1972 [799-1972] days vs 244 [64-838] days, Pâ¯=â¯0.0112). Being from a more recent cohort was associated with better 1-year survival. Renal recovery occurred in eight patients (13.1%) at 30 days and its cumulative incidence increased to 73% (27/37 patients with available data) at 1 year. Most patients initiated on iHD after LVAD experienced renal recovery within the first year after implantation. Improved survival was observed for patients who received HT and in those from more recent cohorts. Some patients were able to survive on LVAD and iHD support for several years.
Subject(s)
Heart Failure , Heart Transplantation , Heart-Assist Devices , Humans , Middle Aged , Heart-Assist Devices/adverse effects , Heart Transplantation/adverse effects , Renal Dialysis , Treatment OutcomeSubject(s)
Angiotensins , Heart Failure , Humans , Neprilysin , Heart Failure/drug therapy , Valsartan , Angiotensin Receptor Antagonists/pharmacology , Angiotensin Receptor Antagonists/therapeutic use , Stroke Volume , Aminobutyrates/pharmacology , Aminobutyrates/therapeutic use , Tetrazoles , Drug Combinations , Biphenyl CompoundsABSTRACT
PURPOSE OF REVIEW: Hypertension (HTN) that can be attributed to a particular source is known as secondary HTN (SH). Often, SH is difficult to control and thus referred to as resistant HTN, although the two terms are not mutually exclusive. RECENT FINDINGS: A common theme across several contributors to SH are coactivation of the sympathetic drive and hormonal changes, independent of hormonal axis activation. The key to effective management of SH is early recognition and treatment to avoid catastrophic cardiovascular disease effects and mortality. SUMMARY: This review article provides a contemporary summary of the conditions associated with SH and briefly reviews diagnostics and management.
Subject(s)
Cardiovascular Diseases , Hypertension , Humans , Hypertension/diagnosis , Hypertension/therapySubject(s)
Heart Failure , Humans , Heart Failure/diagnosis , Heart Failure/therapy , Risk Assessment , Predictive Value of TestsSubject(s)
COVID-19 , Heart Failure , Humans , Pandemics , Heart Failure/epidemiology , Heart Failure/therapyABSTRACT
The prevalence of obesity has reached pandemic proportions worldwide and certainly in the United States. Obesity is a well-established independent risk factor for development of many cardiovascular diseases (CVD), including heart failure, coronary heart disease, atrial fibrillation, and hypertension. Therefore, it is logical to expect obesity would have a strong correlation with CVD mortality. However, a substantial body of literature demonstrates a paradox with improved prognosis of overweight and obese patients with established CVD compared to lean patients with the identical CVD. Surprisingly, similar data has also shown that cardiovascular fitness, rather than weight loss alone, influences the relationship between obesity and mortality in those with established CVD. The impact of fitness, exercise, physical activity (PA), and weight loss and their relationship to the obesity paradox are all reviewed here.
Subject(s)
Cardiovascular Diseases , Humans , United States , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Obesity Paradox , Obesity/diagnosis , Obesity/epidemiology , Obesity/therapy , Risk Factors , Weight Loss , Body Mass IndexABSTRACT
Hyponatremia is a well-established marker of adverse outcomes in chronic heart failure (HF) but not well studied in patients with left ventricular assist device (LVAD). This is a retrospective study, single center study of HM3 [Abbott, USA] LVAD implants. We divided our population based on their sodium prior to LVAD implantation - hyponatremia if <135 mEq/L and normal sodium if 135-145 mEq/L. We compared postoperative and long-term outcomes. A total of 195 patients were included, preimplant hyponatremia was present in 40% with a sodium of 132.1 ± 2.1 vs 137.8 ± 1.9 mEq/L in the normal sodium group. No differences were observed in the postoperative or long-term outcomes. Preimplant hyponatremia was not associated with mortality or HF admissions, likely due to adequate left ventricular unloading and resolution of the mechanisms that lead to hyponatremia. These results suggest that optimization of mild hyponatremia may not be critical and should not delay LVAD placement.
Subject(s)
Heart Failure , Heart-Assist Devices , Hyponatremia , Humans , Retrospective Studies , Heart-Assist Devices/adverse effects , Hyponatremia/etiology , Hyponatremia/complications , Heart Failure/epidemiology , Sodium , Treatment OutcomeABSTRACT
Early detection and risk stratification of patients with heart failure (HF) are crucial to improve outcomes. Given the complexity of the pathophysiological processes of HF and the involvement of multi-organ systems in different stages of HF, clinical prognostication of HF can be challenging. In this regard, several biomarkers have been investigated for diagnosis, screening, and risk stratification of HF patients. These biomarkers can be classified as biomarkers of myocardial stretch such as B-type natriuretic peptide, biomarkers of neurohormonal activation, biomarkers of inflammation and oxidative stress and biomarkers of cardiac hypertrophy, fibrosis and remodeling. In this paper, we summarize current evidence supporting the use of selected biomarkers in HF. We review their diagnostic, prognostic and therapeutic role in the management of HF. We also discuss potential factors limiting the use of these novel biomarkers in the clinical practice and highlight the challenges of adopting a multi-biomarker strategy.
Subject(s)
Heart Failure , Biomarkers , Humans , Inflammation , Natriuretic Peptide, Brain , PrognosisABSTRACT
Overweight and obesity adversely impact cardiac structure and function, affecting systolic and diastolic ventricular function. Epidemiologic studies have documented an obesity paradox in large heart failure cohorts, where overweight and obese individuals with established heart failure have a better short- and medium-term prognosis compared with leaner patients; this relationship is strongly impacted by level of cardiorespiratory fitness. There are implications for therapies aimed at increasing lean mass as well as weight loss and improvements in quality of diet for the prevention and treatment of heart failure and concomitant obesity to improve cardiorespiratory fitness.
Subject(s)
Heart Failure , Overweight , Body Mass Index , Heart Failure/complications , Heart Failure/epidemiology , Humans , Obesity/complications , Obesity/epidemiology , Overweight/complications , Prognosis , Weight LossSubject(s)
Heart Failure , Comorbidity , Heart Failure/epidemiology , Heart Failure/therapy , HumansSubject(s)
Heart Failure , Heart Failure/diagnosis , Heart Failure/epidemiology , Humans , Patient ReadmissionABSTRACT
Data on the efficacy and safety of the combination of warfarin and dual-antiplatelet therapy compared with warfarin and mono-antiplatelet therapy (MAPT) in patients with left ventricular assist devices (LVAD) remains scarce. Single-center study of 130 consecutive patients with durable LVAD. Baseline demographics, antithrombotic and antiplatelet regimen, and outcomes were compared between patients receiving warfarin plus dual-antiplatelet therapy (Group 1) and warfarin plus MAPT (Group 2). Antiplatelet therapy was assessed at hospital discharge post-LVAD implant and included aspirin, clopidogrel and dipyridamole. Outcomes at 1-year were assessed in each group. All patients were on aspirin and warfarin. No significant differences with regards to age, gender or ethnicity were noted at baseline between the two groups. Group 1 was more likely to have higher lactate dehydrogenase LDH levels at discharge and a history of stroke. No significant differences in international normalized ratio INR, hemoglobin or hematocrit were noted at discharge. During the study period, 48 patients had gastrointestinal bleeding events: 28 of 68 (41.2%) in Group 1 vs 20 of 62 (32.2%) in Group 2 (Pâ¯=â¯0.293). At 1year, no statistically significant differences were noted in gastrointestinal bleeding (Group 1=27.90% vs Group 2â¯=â¯25.80, Pâ¯=â¯0.784), ischemic stroke (Group 1â¯=â¯8.8% vs group 2â¯=â¯6.5%, Pâ¯=â¯0.612), hemorrhagic stroke (Group 1â¯=â¯4.4% vs group 2â¯=â¯3.2%, Pâ¯=â¯0.725) or mortality (Group 1â¯=â¯5.9% vs Group 2â¯=â¯1.6%, Pâ¯=â¯0.206). Rates of pump thrombosis however were lower in Group 1 (Group 1â¯=â¯0% vs Group 2â¯=â¯6.5%, Pâ¯=â¯0.033). Our study showed a high prevalence of triple-therapy antithrombotic use in LVAD patients with no significant differences in bleeding, stroke or survival. However, the risk for pump thrombosis was lower at 1-year when compared to patient receiving MAPT.
Subject(s)
Heart-Assist Devices , Stroke , Thrombosis , Anticoagulants/adverse effects , Aspirin/adverse effects , Drug Therapy, Combination , Fibrinolytic Agents/adverse effects , Gastrointestinal Hemorrhage/chemically induced , Gastrointestinal Hemorrhage/drug therapy , Heart-Assist Devices/adverse effects , Humans , Platelet Aggregation Inhibitors/adverse effects , Stroke/epidemiology , Stroke/etiology , Stroke/prevention & control , Thrombosis/drug therapy , Warfarin/adverse effectsABSTRACT
Coronary angiography remains the gold standard post-transplant screening test for cardiac allograft vasculopathy. This procedure has traditionally been performed via femoral approach. Data on safety and efficacy of radial approach in cardiac transplant patients remains scarce. Single center retrospective study including all cardiac transplant patients who underwent coronary angiography via transradial approach (TRA) or transfemoral approach (TFA). Safety and efficacy outcomes were compared between the 2 groups. Primary end points included major bleeding, vascular complications, crossover to femoral approach, contrast use and radiation exposure. A total of 201 patients were included. 96 patients (47.8%) underwent angiography via TRA. At baseline, no significant differences with regards to age, gender, or traditional risk factors such as HTN, DM, hyperlipidemia were noted between the 2 groups. Most patients underwent intravascular ultrasound (nâ¯=â¯179, 89%) with no statistically significant differences between the 2 groups (TRA: 90.6% vs TFA: 87.6%, Pâ¯=â¯0.5). Additionally, there were no statistically significant differences in radiation exposure, amount of contrast use and fluoroscopy time between the 2 groups. Although there were trends toward increased bleeding among TFA group, these were not statistically significant and were mostly driven by access site hematomas. Use of TRA increased over time and Conversion from TRA to TFA was low (nâ¯=â¯4, 4.2%). Coronary angiography via the radial approach in cardiac transplant recipients is feasible, safe and is associated with low a risk of bleeding with no significant increase in radiation exposure when compared to the traditional femoral approach.